The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation

Kidney International

Volumn 78, Issue 11, 2010, Pages 1075-1079

  Geissler, Edward K ^a   Schlitt, Hans J ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

fibrosis; immunosuppression; malignancy; rapamycin; tolerance

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN;

ACNE; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CELL GROWTH; DELAYED GRAFT FUNCTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; EDEMA; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; MOUTH ULCER; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SIGNAL TRANSDUCTION; SKIN DEFECT; WOUND HEALING IMPAIRMENT;

EID: 78349313076     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.324     Document Type: Short Survey

References (34)

1. Eng CP, Sehgal SN, Vézina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot 1984; 37: 1231-1237.
2. Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-442.
3. Ruiz JC, Campistol JM, Sanchez-Fructuoso A et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006; 21: 3252-3257.
4. Torras J, Herrero-Fresneda I, Gulias O et al. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol Dial Transplant 2009; 24: 3632-3640.
5. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
6. Webster AC, Lee VW, Chapman JR et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
7. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817.
8. Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 2010; 23: 133-142.
9. Harrison DE, Strong R, Sharp ZD et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-395.
10. Lee DF, Kuo HP, Chen CT et al. IKKb suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007; 130: 440-455.
11. Nicklin P, Bergman P, Zhang B et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-534.
12. Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-g activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004; 53: 2748-2756.
13. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.
14. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
15. Koehl G, Andrassy J, Guba M et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319-1326.
16. Dere R, Wilson PD, Sandford RN et al. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS One 2010; 5: e9239.
17. Min/+ mice. Oncogene 2010; 29: 1553-1560.
18. De Gruijl FR, Koehl GE, Voskamp P et al. Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. Int J Cancer 2009; 127: 796-804.
19. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743-4748.
20. + T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010; 32: 67-78.
21. Egli A, Köhli S, Dickenmann M et al. Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs. Transplantation 2009; 88: 1161-1168.
22. Mueller NJ. New immunosuppressive strategies and the risk of infection. Transpl Infect Dis 2008; 10: 379-384.
23. + T-cell differentiation. Immunol Rev 2010; 235: 234-243.
24. Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
25. Li Y, Zheng XX, Li XC et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66: 1387-1388.
26. + cells. J Exp Med 2008; 205: 565-574.
27. + T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018-7031.
28. Weichhart T, Costantino G, Poglitsch M et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: 565-577.
29. Rahimi RA, Andrianifahanana M, Wilkes MC et al. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-b. Cancer Res 2009; 69: 84-93.
30. Wang S, Wilkes MC, Leof EB et al. Noncanonical TGF-b pathways, mTORC1 and Ab1, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010; 298: F142-F149.
31. Pontrelli P, Rossini M, Infante B et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008; 85: 125-134.
32. Servais A, Meas-Yedid V, Toupance O et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9: 2552-2560.
33. Bridle KR, Popa C, Morgan ML et al. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl 2009; 15: 1315-1324.
34. Schnitzbauer AA, Zuelke C, Graeb C et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190.